Cargando…
Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Breast Cancer Society
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981989/ https://www.ncbi.nlm.nih.gov/pubmed/36762785 http://dx.doi.org/10.4048/jbc.2022.25.e50 |
| _version_ | 1784900226671181824 |
|---|---|
| author | Sorscher, Steven |
| author_facet | Sorscher, Steven |
| author_sort | Sorscher, Steven |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9981989 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Korean Breast Cancer Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99819892023-03-04 Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly Sorscher, Steven J Breast Cancer Commentary Korean Breast Cancer Society 2022-12-05 /pmc/articles/PMC9981989/ /pubmed/36762785 http://dx.doi.org/10.4048/jbc.2022.25.e50 Text en © 2023 Korean Breast Cancer Society https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Commentary Sorscher, Steven Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly |
| title | Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly |
| title_full | Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly |
| title_fullStr | Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly |
| title_full_unstemmed | Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly |
| title_short | Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly |
| title_sort | biomarkers that predict an unclear benefit from adjuvant trastuzumab, pertuzumab and pembrolizumab when those same drugs were given neoadjuvantly |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981989/ https://www.ncbi.nlm.nih.gov/pubmed/36762785 http://dx.doi.org/10.4048/jbc.2022.25.e50 |
| work_keys_str_mv | AT sorschersteven biomarkersthatpredictanunclearbenefitfromadjuvanttrastuzumabpertuzumabandpembrolizumabwhenthosesamedrugsweregivenneoadjuvantly |